dc.contributor.author |
Bergmann, Julie N. |
|
dc.contributor.author |
Wanyenze, Rhoda K. |
|
dc.contributor.author |
Makumbi, Fred |
|
dc.contributor.author |
Naigino, Rose |
|
dc.contributor.author |
Kiene, Susan M. |
|
dc.contributor.author |
Stockman, Jamila K. |
|
dc.date.accessioned |
2021-01-01T21:58:00Z |
|
dc.date.available |
2021-01-01T21:58:00Z |
|
dc.date.issued |
2017 |
|
dc.identifier.issn |
1090-7165 |
|
dc.identifier.uri |
http://combine.alvar.ug/handle/1/48116 |
|
dc.description.abstract |
Vertical transmission of HIV is responsible for about 14 % of new HIV cases reported each year in sub-Saharan Africa. Barriers that prevent women from accessing and using antiretroviral medications (ARVs) for themselves and their infants perpetuate the epidemic. To identify influences on access to and use of infant HIV health services, specifically nevirapine administration, we conducted a mixed methods study among HIV-positive women in Uganda. This included a cross-sectional survey (n = 384) and focus group discussions (n = 6, 5-9 participants each). Of the 384 women, 80 % gave nevirapine to their infants within 72 h of birth. Factors independently associated with nevirapine administration were lack of maternal adherence to ARVs (AOR 3.55, 95 % CI 1.36-9.26) and attending a support group (AOR 2.50, 95 % CI 1.06-5.83). Non-health facility births were inversely related to nevirapine use (AOR 0.02, 95 % CI 0.003-0.09). Focus group discussions identified four themes impacting access and use: attending a support group, health care worker attitudes, lack of partner support, and poor health messaging regarding ARVs. Improving health care worker messaging regarding ARVs and providing women with needed support to access and use infant ARV prophylaxis is critical to overcoming access barriers. Eliminating these barriers may prevent numerous HIV infections each year saving the lives of many HIV-exposed infants. |
|
dc.description.sponsorship |
University of California, San DiegoUniversity of California System |
|
dc.description.sponsorship |
Ugandan Ministry of Health Global Fund [UGD-708-G07-H] |
|
dc.description.sponsorship |
National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K01DA031593] |
|
dc.description.sponsorship |
National Institute of Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [L60MD003701] |
|
dc.description.sponsorship |
NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K01DA031593, K01DA031593, K01DA031593, K01DA031593, K01DA031593] Funding Source: NIH RePORTER |
|
dc.language |
English |
|
dc.publisher |
SPRINGER/PLENUM PUBLISHERS |
|
dc.relation.ispartof |
AIDS and Behavior |
|
dc.subject |
Hiv-Exposed Infants |
|
dc.subject |
Art Adherence |
|
dc.subject |
Vertical Transmission Of Hiv |
|
dc.subject |
Prevention Of Mother To Child Transmission |
|
dc.subject |
Sub-Saharan Africa |
|
dc.title |
Maternal Influences on Access to and Use of Infant ARVs and HIV Health Services in Uganda |
|
dc.type |
Article |
|
dc.identifier.isi |
000408092300014 |
|
dc.identifier.doi |
10.1007/s10461-016-1528-1 |
|
dc.identifier.pmid |
2755 |
|
dc.publisher.city |
NEW YORK |
|
dc.publisher.address |
233 SPRING ST, NEW YORK, NY 10013 USA |
|
dc.identifier.eissn |
1573-3254 |
|
dc.identifier.volume |
21 |
|
dc.identifier.issue |
9 |
|
dc.identifier.spage |
2693 |
|
dc.identifier.epage |
2702 |
|
dc.subject.wc |
Public, Environmental & Occupational Health |
|
dc.subject.wc |
Social Sciences, Biomedical |
|
dc.subject.sc |
Public, Environmental & Occupational Health |
|
dc.subject.sc |
Biomedical Social Sciences |
|
dc.description.pages |
10 |
|
dc.subject.kwp |
Active Antiretroviral Therapy |
|
dc.subject.kwp |
To-Child Transmission |
|
dc.subject.kwp |
Follow-Up |
|
dc.subject.kwp |
Infected Children |
|
dc.subject.kwp |
Randomized-Trial |
|
dc.subject.kwp |
Prevention |
|
dc.subject.kwp |
Care |
|
dc.subject.kwp |
Intrapartum |
|
dc.subject.kwp |
Challenges |
|
dc.subject.kwp |
Zidovudine |
|
dc.description.affiliation |
Univ Calif San Diego, Div Global Publ Hlth, Dept Med, 9500 Gilman Dr,MC 0507, La Jolla, CA 92093 USA |
|
dc.description.affiliation |
San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA |
|
dc.description.affiliation |
Makerere Univ, Sch Publ Hlth, Kampala, Uganda |
|
dc.description.email |
jnbergmann@ucsd.edu |
|
dc.description.corr |
Bergmann, JN (corresponding author), Univ Calif San Diego, Div Global Publ Hlth, Dept Med, 9500 Gilman Dr,MC 0507, La Jolla, CA 92093 USA.; Bergmann, JN (corresponding author), San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. |
|
dc.description.orcid |
Kiene, Susan/0000-0001-8922-5289 |
|